Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
| 대상 질환 | Epileptic Encephalopathy, Continuous Spike and Wave During Sleep |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Neurocrine Biosciences |
| 상태 | 조기 종료 |
| 참여자 수 | 19 명 |
| 중재(약물) | NBI-827104 |
| 시작일 | 2022년 6월 7일 |
| 완료일 | 2025년 1월 27일 |
| 결과 공개일 | 2026년 2월 13일 |
요약
The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).
The Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs)
| NBI-827104 | 2 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner